| Code | CSB-RA023441MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar referenced to the antibody described in patent WO2019075417A1, targeting TFRC (transferrin receptor), also known as TfR1 or CD71. TFRC is a type II transmembrane glycoprotein that mediates cellular iron uptake through receptor-mediated endocytosis of iron-bound transferrin. Iron is essential for DNA synthesis, mitochondrial function, and cellular proliferation. TFRC is ubiquitously expressed but significantly upregulated in cancer cells to meet their elevated iron demands for rapid proliferation. Overexpression of TFRC is observed across multiple malignancies, including breast, pancreatic, ovarian, renal, and nasopharyngeal cancers, where high expression correlates with tumor aggressiveness, metastasis, and poor prognosis. TFRC expression is regulated by oncogenic pathways involving c-MYC, HIF-1, and PI3K/AKT signaling. The reference antibody is designed to target TFRC for therapeutic or diagnostic applications, potentially exploiting its high expression on cancer cells and its internalization properties for drug delivery. This biosimilar provides researchers with a valuable tool for investigating iron metabolism in cancer, studying TFRC-mediated endocytosis, and exploring therapeutic strategies targeting iron-dependent tumor growth. It supports research into ferroptosis, antibody-drug conjugate development, and blood-brain barrier transcytosis mechanisms.
There are currently no reviews for this product.